

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-74. (Canceled)

75. (Currently Amended) The kit of ~~claim 71~~any one of claims 86-88, wherein said neoplasia is a relapsed lymphoma or leukemia.

76.-81. (Canceled)

82. (Currently Amended) The kit of ~~claim 81~~any one of claims 86-88, wherein the pH of the interior and exterior of said liposome is approximately 4.0.

83. (Canceled)

84. (Currently Amended) The kit of ~~claim 83~~any one of claims 86-88, wherein said liposome comprises sphingomyelin and cholesterol at a ratio of about 55/45 (mol% sphingomyelin/mol% cholesterol).

85. (Currently Amended) The kit of ~~claim 77~~any one of claims 86-88, wherein the pH of the alkaline phosphate buffer solution is approximately 9.0.

86. (Previously Presented) A kit for use in the treatment of a neoplasia in a mammal, said kit comprising:

- (a) a first vial comprising a solution comprising vincristine sulfate at a concentration of approximately 1 mg/ml, mannitol at a concentration of approximately 100 mg/ml, wherein said solution has a pH in the range of 3.5 to 5.5;
- (b) a second vial comprising a citrate-buffered solution comprising liposomes comprising sphingomyelin and cholesterol in a ratio of 75/25 (mol% sphingomyelin/mol% cholesterol) to 50/50 (mol% sphingomyelin/mol% cholesterol);
- (c) a third vial comprising a buffer solution comprising dibasic sodium phosphate heptahydrate at a concentration of approximately 14.2 mg/ml; and
- (d) instructions for the use of said kit to prepare a liposomal composition useful in the treatment of a neoplasia in a mammal.

87. (Currently Amended) A kit for use in the treatment of a neoplasia in a mammal, said kit comprising:

- (a) a first vial comprising a vincristine solution, wherein said vincristine is present at a concentration of 1 mg/ml to 5 mg/ml, wherein said solution has a pH in the range of 3.5 to 5.5;
- (b) a second vial comprising liposomes in a citrate-buffered solution, wherein said liposomes comprise sphingomyelin and cholesterol in a ratio of 75/25 (mol% sphingomyelin/mol% cholesterol) to 50/50 (mol% sphingomyelin/mol% cholesterol), and wherein the pH of the interior and exterior of said liposomes is acidic;
- (c) a third vial comprising an alkaline phosphate buffer solution having a pH higher than the pH of the solution of the second vial, such that combining the solutions of the second and third vials results in the pH of the exterior of said liposomes being neutral; and
- (d) instructions for the use of said kit to prepare liposomal compositions useful in the treatment of a neoplasia in a mammal.

88. (New) A kit for use in the treatment of a neoplasia in a mammal, said kit comprising:

(a) a first vial comprising a solution comprising vincristine at a concentration of approximately 1 mg/ml, mannitol at a concentration of approximately 100 mg/ml, wherein said solution has a pH in the range of 3.5 to 5.5;

(b) a second vial comprising a citrate-buffered solution comprising liposomes comprising sphingomyelin and cholesterol in a ratio of 75/25 (mol% sphingomyelin/mol% cholesterol) to 50/50 (mol% sphingomyelin/mol% cholesterol);

(c) a third vial comprising a buffer solution comprising dibasic sodium phosphate heptahydrate at a concentration of approximately 14.2 mg/ml; and

(d) instructions for the use of said kit to prepare a liposomal composition useful in the treatment of a neoplasia in a mammal.